Vanguard Discloses 12.96% Stake in BioCryst Pharma

TL;DR

**Vanguard owns 12.96% of BioCryst, signaling institutional confidence.**

AI Summary

The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership in BioCryst Pharmaceuticals Inc. As of December 29, 2023, Vanguard beneficially owned 27,049,709 shares of BioCryst's Common Stock, representing 12.96% of the company. This filing indicates a significant, albeit passive, stake by a large institutional investor, which can signal confidence in the company's long-term prospects to current and potential shareholders.

Why It Matters

This filing shows that a major institutional investor, The Vanguard Group, holds a substantial portion of BioCryst Pharmaceuticals, which can be seen as a vote of confidence in the company's future. For investors, this indicates that a large, sophisticated entity sees value in the stock.

Risk Assessment

Risk Level: low — This filing is an amendment to a passive ownership stake, indicating no immediate change in control or strategy, thus posing low risk.

Analyst Insight

A smart investor would note Vanguard's substantial, passive stake as a potential indicator of long-term institutional confidence in BioCryst, but should conduct further due diligence on BioCryst's fundamentals and future prospects rather than relying solely on this filing.

Key Numbers

• 27,049,709 — Shares Beneficially Owned (The total number of BioCryst Pharmaceuticals Inc. common stock shares owned by The Vanguard Group as of December 29, 2023.)
• 12.96% — Percentage of Class (The percentage of BioCryst Pharmaceuticals Inc.'s common stock that The Vanguard Group beneficially owns, indicating a significant institutional stake.)

Key Players & Entities

• The Vanguard Group (company) — reporting person and beneficial owner
• BioCryst Pharmaceuticals Inc (company) — subject company
• 27,049,709 shares (dollar_amount) — total shares beneficially owned by Vanguard
• 12.96% (dollar_amount) — percentage of BioCryst's Common Stock owned by Vanguard
• December 29, 2023 (date) — date of event requiring the filing
• February 13, 2024 (date) — filing date of the SC 13G/A

Forward-Looking Statements

• Vanguard will maintain a significant, passive stake in BioCryst Pharmaceuticals Inc. (The Vanguard Group) — high confidence, target: December 29, 2024

FAQ

Filing Documents

• tv0435-biocrystpharmaceutica.htm (SC 13G/A) — 11KB
• 0001104659-24-020432.txt ( ) — 13KB

(a) - Name of Issuer

Item 1(a) - Name of Issuer: BioCryst Pharmaceuticals Inc

(b) - Address of Issuer's Principal Executive Offices

Item 1(b) - Address of Issuer's Principal Executive Offices: 4505 Emperor Boulevard, Suite 200 Durham, NC 27703-8457

(a) - Name of Person Filing

Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930

(b) – Address of Principal Business Office or, if none, residence

Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355

(c) – Citizenship

Item 2(c) – Citizenship: Pennsylvania

(d) - Title of Class of Securities

Item 2(d) - Title of Class of Securities: Common Stock

(e) - CUSIP Number

Item 2(e) - CUSIP Number 09058V103

- Type of Filing

Item 3 - Type of Filing: This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E).

- Ownership

Item 4 - Ownership: (a) Amount Beneficially Owned: (b) Percent of Class: (c) Number of shares as to which such person has: (i) sole power to vote or direct to vote: (ii) shared power to vote or direct to vote: (iii) sole power to dispose of or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of: Comments: The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.

- Ownership of Five Percent or Less of a Class

Item 5 - Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following

- Ownership of More Than Five Percent on Behalf of Another Person

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person: The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%. Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company: Not applicable

- Identification and Classification of Members of Group

Item 8 - Identification and Classification of Members of Group: Not applicable

- Notice of Dissolution of Group

Item 9 - Notice of Dissolution of Group: Not applicable

- Certification

Item 10 - Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2024 By /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

View Full Filing

View this SC 13G/A filing on SEC EDGAR